Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06350110
Other study ID # ESBI202492
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 10, 2024
Est. completion date December 28, 2025

Study information

Verified date April 2024
Source Essen Biotech
Contact JAMAL ALKHAYER
Phone +97333799773
Email ceo@essen-biotech.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.


Description:

Systemic lupus erythematosus (SLE) is a type of autoimmune disorder characterized by the creation of autoantibody-generating immune complexes, affecting various systems and organs. In SLE, autoreactive B cells can self-activate and morph into plasma cells that produce a high volume of autoantibodies. These cells can also expose their own antigens to autoimmune T cells, thereby stimulating T cells and leading to the release of inflammatory substances. Conventional treatment for SLE focuses on achieving prolonged remission. In contrast, CD19-BCMA CAR-T cells offer a potential solution by eradicating the abnormal B cells responsible for antibody production. This allows for the rebuilding of the immune system and the restoration of normal immune function in patients, potentially leading to a life free from medication. This highlights the promising potential of CAR-T therapy in treating SLE.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 75
Est. completion date December 28, 2025
Est. primary completion date December 10, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - 18-90 years old; - Total score = 10 on the EULAR/ACR 2019 SLE classification criteria. - SELENA-SLEDAI=8. - Patients with CD19+ B-cell. - Hemoglobin=85 g/L. - WBC=2.5×10^9/L. - NEUT=1×10^9/L. - BPC=50×10^9/L. - AST/ALT below 2 times the upper limit of normal; Creatinine clearance =30 mL/min; blood bilirubin =2.0 mg/dl; echocardiography indicates that the ejection fraction is =50%. - Adequate venous access for apheresis, and no other contraindications for leukapheresis. - Women of childbearing age should have a negative serum or urine pregnancy test at screening and baseline. - Subjects agree to take effective contraceptive measures during the trial until at least 1 year after CAR-T cells infusion. - Agree to attend follow-up visits as required. - Voluntary participation and informed consent signed by the patient or his/her legal/authorized representative. Exclusion Criteria: - Renal disease: severe lupus nephritis (serum creatinine > 2.5 mg/dL or 221 µmol/L) within 8 weeks --Prior to leukapheresis, or subjects who need hemodialysis. - CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident [CVA], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts. - Patients with serious lesions and a history of present illness of vital organs such as the heart, liver,kidney blood and endocrine system. - Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers; - Received immunosuppressive therapy within 1 week prior to leukapheresis. - Patients with HIV infection; Active infection of hepatitis B virus or hepatitis C virus. - Patients with syphilis infection. - The presence or suspicion of an active fungal, bacterial, viral or other infection that cannot be controlled during screening. - Received live vaccine treatment within 4 weeks prior to screening. - Severe allergies or hypersensitivity. - Contraindication to cyclophosphamide in combination with fludarabine. - Subjects who have undergone major surgery within 2 weeks prior to signing the informed consent form, or who are scheduled to have surgery (other than local anesthetic surgery) during the trial or within 2 weeks of the infusion. - Cannula or drainage tubes other than central venous catheters. - Pregnant or lactating women, or subjects who plan to have children within 1 year of treatment; - Subjects with prior CD19 or BCMA-targeted therapy. - Participated in any clinical study within 3 months prior to enrollment. - Subjects with malignant tumour, except for Non-melanoma Skin Cancer with PFS>5yr; Cervical Cancer in situ; Bladder Cancer; Breast Cancer.

Study Design


Intervention

Biological:
CD19- BCMA CAR-T cells
The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies. Treatment Regimen: Patients in the trial will undergo the following regimen: Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy. Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2. CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0. Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses.

Locations

Country Name City State
China District one hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Essen Biotech

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/BCMA chimeric antigen receptor (CAR) T cells Will be recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 at three dose levels until the maximum tolerated dose (MTD) is determined. 28 days
Secondary Rate of successful manufacture and expansion of the CD19/BCMA chimeric antigen receptor (CAR) T cells satisfy the targeted dose level and meet the required release specifications outlined in the Certificate of Analysis (COA) 10-14 days after apheresis or thawing of cryopreserved peripheral blood mononuclear cell
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2